Exelixis Inc Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Exelixis Inc (EXEL) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$1.60 million for the 12-month period ending 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-10
- Exelixis Inc valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2018-12-28 was $244.10M.
- Exelixis Inc valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2026 was -$1.60M.
- Exelixis Inc valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was -$3.00M, a 151.72% decline from fiscal 2023.
- Exelixis Inc valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $5.80M, a 19.44% decline from fiscal 2022.
- Exelixis Inc valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $7.20M, a 148.28% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|---|
| 2026-01-02 | -$1.60M 10-K · filed 2026-02-10 | ||
| 2025-01-03 | -$3.00M 10-K · filed 2026-02-10 | $3.00M 10-K · filed 2025-02-11 | |
| 2023-12-29 | $5.80M 10-K · filed 2025-02-11 | ||
| 2022-12-30 | $7.20M 10-K · filed 2024-02-06 | ||
| 2021-12-31 | $2.90M 10-K · filed 2023-02-07 | ||
| 2021-01-01 | $5.50M 10-K · filed 2022-02-18 | ||
| 2020-01-03 | $3.50M 10-K · filed 2021-02-11 | ||
| 2018-12-28 | $244.10M 10-K · filed 2020-02-25 | -$360.80M 10-K · filed 2020-02-25 | |
| 2017-12-29 | -$210.10M 10-K · filed 2019-02-22 | ||
| 2016-12-31 | $92.70M 10-K · filed 2017-02-27 | ||
| 2016-12-30 | $92.70M 10-K · filed 2018-02-26 | ||
| 2016-01-01 | $7.90M 10-K · filed 2018-02-26 | ||
| 2015-12-31 | $7.90M 10-K · filed 2017-02-27 | $12.40M 10-K · filed 2016-02-29 | |
| 2014-12-31 | $88.80M 10-K · filed 2017-02-27 | -$89.70M 10-K · filed 2015-03-02 | |
| 2013-12-31 | -$16.80M 10-K · filed 2016-02-29 | $16.80M 10-K · filed 2014-02-20 | |
| 2012-12-31 | $6.80M 10-K · filed 2015-03-02 | ||
| 2011-12-31 | -$49.70M 10-K · filed 2014-02-20 | $49.70M 10-K · filed 2012-02-22 | |
| 2010-12-31 | $25.20M 10-K · filed 2013-02-21 | ||
| 2009-12-31 | $52.40M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |